ESPERITE tackles Autism with revolutionary Genetic test
(Thomson Reuters ONE) -
REALITY, the First High-tech Genetic Test for Autism, Now for Everyone
The Latest Release from ESPERITE's Neurology, Oncology, Metabolic Disorders and
Prenatal Genetic Testing Pipeline
Geneva, Switzerland - 5 February 2015
ESPERITE announced today the launch of REALITY, the new-generation genetic
predisposition test for autism. REALITY is pivotal for tackling autism because
the child can be tested at an early age, even at birth. This allows for early
intervention which is the most effective approach to alter how autism develops.
REALITY is a risk-free, convenient, affordable and reliable test, with results
available in less than 3 weeks. ESPERITE has acquired exclusive worldwide
distribution rights (excluding the United States) for IntegraGen's autism test,
the first of its kind marketed in the United States.
REALITY enables early life intervention helping physicians tailor therapy to the
child's genetic profile, lessening anxiety in parents. Early interventions
under the age of 3 -benefiting from the increased plasticity of the brain-
stimulate the brain receptors in autistic children to respond in a similar
manner to a child without autism. Early intervention improves communication
skills, IQ scores, cognitive and adaptive behavior, allowing children to become
more autonomous, follow mainstream education and, when adult, obtain employment
and live independently.
Autism is one of the most frequent and difficult to diagnose childhood
disorders, with a growing prevalence rate (1:150 children across Europe)
affecting all racial, ethnic, and socioeconomic groups. The chance of autism in
younger brothers of affected children is 25.9%.
The economic impact of autism with estimated annual costs of $283 billion in the
US and UK alone, is more than any other medical condition and greater than the
cost of cancer, heart disease and stroke combined. "We are paying for the costs
of inaction and the costs of 'inappropriate action,'" says Dr. David Mandell,
Director of the Center for Mental Health Policy and Services Research,
University of Pennsylvania. "What these figures show is a clear need for more
effective interventions to treat autism, ideally in early life" declares
Professor Martin Knapp, Director of the Personal Social Services Research Unit,
LSE.
Frederic Amar, CEO of ESPERITE group: "REALITY provides parents and physicians
the key genetic information to best tackle autism through early intervention,
fostering a proactive and responsible approach towards doing what is best for
the child."
ESPERITE, through its predictive medicine arm GENOMA SA, is at the forefront of
technological and scientific innovation. Its multimillion dollar genetic
platform for clinical diagnostics is the largest in Europe; a highly efficient
NGS platform with the capacity to process 75'000 samples per year as of today.
ESPERITE will install Thermo Fisher Life Technology satellite sequencing
platforms in the countries where it operates, all connected to its NGS Cloud.
2015 marks the beginning of a new era for personalized medicine. ESPERITE is
leading this paradigm shift and will communicate shortly the launching of new
genetic tests.
About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is the leading
international company in regenerative and predictive medicine since 2000,
operational in 40 countries with a network of 6'000 clinics worldwide. ESPERITE
serves clients in its state-of-the-art lab facilities in Geneva coupled with
ultra-modern processing and storage facilities in Belgium, Switzerland, Germany,
Dubai, South Africa and Portugal. Its family stem cell bank, CryoSave, stores
almost 275'000 samples from umbilical cord blood and cord tissue.
To learn more about the ESPERITE group, or to book an interview with CEO
Frederic Amar: +31 575 548 998 - ir(at)esperite.com or visit the websites at
www.esperite.com and www.genoma.com.
ESPERITE launch REALITY:
http://hugin.info/143308/R/1891985/670078.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
[HUG#1891985]
Unternehmensinformation / Kurzprofil:
Datum: 05.02.2015 - 07:18 Uhr
Sprache: Deutsch
News-ID 369335
Anzahl Zeichen: 5112
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ESPERITE tackles Autism with revolutionary Genetic test"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
